CN113368300A - EPS and mussel extract compounded dressing for repairing skin barrier and preparation method thereof - Google Patents
EPS and mussel extract compounded dressing for repairing skin barrier and preparation method thereof Download PDFInfo
- Publication number
- CN113368300A CN113368300A CN202110604155.6A CN202110604155A CN113368300A CN 113368300 A CN113368300 A CN 113368300A CN 202110604155 A CN202110604155 A CN 202110604155A CN 113368300 A CN113368300 A CN 113368300A
- Authority
- CN
- China
- Prior art keywords
- percent
- mussel extract
- eps
- skin barrier
- dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000237536 Mytilus edulis Species 0.000 title claims abstract description 39
- 235000020638 mussel Nutrition 0.000 title claims abstract description 39
- 239000000284 extract Substances 0.000 title claims abstract description 36
- 230000008591 skin barrier function Effects 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229920002444 Exopolysaccharide Polymers 0.000 claims abstract description 28
- 230000008439 repair process Effects 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241000186660 Lactobacillus Species 0.000 claims abstract description 15
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 15
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 12
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 12
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 12
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract description 12
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 12
- 241001506047 Tremella Species 0.000 claims abstract description 12
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 12
- 229960003237 betaine Drugs 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000003755 preservative agent Substances 0.000 claims abstract description 11
- 230000002335 preservative effect Effects 0.000 claims abstract description 11
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 claims abstract description 11
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 claims abstract description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 10
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 10
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 10
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 10
- 239000000661 sodium alginate Substances 0.000 claims abstract description 10
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 5
- AZJXQVRPBZSNFN-UHFFFAOYSA-N octane-3,3-diol Chemical compound CCCCCC(O)(O)CC AZJXQVRPBZSNFN-UHFFFAOYSA-N 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 3
- 229940035437 1,3-propanediol Drugs 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 229940100573 methylpropanediol Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 abstract description 16
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
- 206010072170 Skin wound Diseases 0.000 abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract description 2
- 229910052708 sodium Inorganic materials 0.000 abstract description 2
- 239000011734 sodium Substances 0.000 abstract description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 210000005069 ears Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000435 effect on ear Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- -1 polysaccharide compounds Chemical class 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an EPS and mussel extract compounded skin barrier repair dressing and a preparation method thereof, wherein the EPS and mussel extract compounded skin barrier repair dressing comprises the following raw materials in percentage by weight: 0.05-0.12 percent of hyaluronic acid, 0.5-0.8 percent of sodium alginate, 0.06-0.15 percent of tremella heteropolysaccharide, 6-8 percent of glycerol, 0.3-1 percent of dihydric alcohol, 1-2 percent of trehalose, 1-2 percent of mannose, 0.02-0.05 percent of lactobacillus exopolysaccharide, 0.03-0.08 percent of mussel extract, 1-2 percent of betaine, 1.5-2.3 percent of amino acid, 1.8-2.5 percent of sodium pyrrolidone carboxylate, 0.01-0.03 percent of preservative and the balance of water. According to the invention, the dressing is prepared by compounding the lactobacillus exopolysaccharide and the mussel extract, combining the tremella heteropolysaccharide, trehalose, mannose and dihydric alcohol, and matching with betaine, PCA sodium and the like in a preferable proportion, so that the prepared dressing has good anti-inflammatory activity, high skin wound healing rate, capability of repairing damaged skin better and faster, stronger skin barrier repair capability and good tolerance.
Description
Technical Field
The invention relates to the technical field of skin barrier repair, in particular to a skin barrier repair dressing compounded by EPS and mussel extracts and a preparation method thereof.
Background
The dressing for repairing the skin barrier has a physical barrier function by forming a protective layer on the surface of the skin wound, and is used for nursing superficial wounds and surrounding skin. The medical dressing sold in the market has a certain adsorption effect on damaged skin, but the medical dressing is often poor in tolerance, hindered in nutrient absorption, slow in skin barrier repair and the like.
Exopolysaccharides (EPS) are polysaccharide compounds secreted outside cells during the growth and metabolism of lactic acid bacteria, and belong to one of microbial polysaccharides. One EPS can improve the rheological property, texture, stability, water retention property, mouthfeel and the like of food; secondly, the EPS has biological activity, and the EPS has a plurality of biological active substances which are beneficial to human health, such as being used as prebiotics for regulating intestinal flora, immunoregulation activity, anti-tumor activity, cholesterol-reducing activity, antioxidation and the like, so the EPS is more applied to the field of food.
The mussel extract is water-soluble protein obtained by fermenting and purifying mussel, and can form a protective film on the skin surface to prevent the invasion of particles, water and microorganisms.
CN107669504A discloses a whitening facial mask based on mussel mucin and a preparation method thereof, the facial mask is mainly used for whitening healthy skin and is not suitable for repairing damaged skin barrier. Therefore, the invention aims to provide a dressing which can repair damaged skin better and faster and has biosafety.
Disclosure of Invention
In view of the above, the invention provides an EPS and mussel extract compounded skin barrier repair dressing and a preparation method thereof, and solves the technical problems.
The technical scheme of the invention is realized as follows: an EPS and mussel extract compound skin barrier repair dressing comprises the following raw materials by weight: 0.05-0.12 percent of hyaluronic acid, 0.5-0.8 percent of sodium alginate, 0.06-0.15 percent of tremella heteropolysaccharide, 6-8 percent of glycerol, 0.3-1 percent of dihydric alcohol, 1-2 percent of trehalose, 1-2 percent of mannose, 0.02-0.05 percent of lactobacillus exopolysaccharide, 0.03-0.08 percent of mussel extract, 1-2 percent of betaine, 1.5-2.3 percent of amino acid, 1.8-2.5 percent of sodium pyrrolidone carboxylate, 0.01-0.03 percent of preservative and the balance of water.
Further, the mass ratio of the lactobacillus exopolysaccharide to the mussel extract is 4: 5.
Further, the dressing comprises the following raw materials in percentage by weight: 0.08% of hyaluronic acid, 0.65% of sodium alginate, 0.10% of tremella heteropolysaccharide, 7% of glycerol, 0.8% of dihydric alcohol, 1.5% of trehalose, 1.5% of mannose, 0.04% of lactobacillus exopolysaccharide, 0.05% of mussel extract, 1.5% of betaine, 1.8% of amino acid, 2.2% of sodium pyrrolidone carboxylate, 0.02% of preservative and the balance of water.
Further, the dihydric alcohol is at least one of 1, 3-propanediol, dipropylene glycol, butylene glycol, methyl propanediol and ethyl hexanediol. Furthermore, the dihydric alcohol is prepared from butanediol, methyl propylene glycol and ethyl hexanediol according to a mass ratio of 0.2: 0.5: 0.3.
Further, the preparation method of the dressing comprises the following steps:
(1) weighing the raw materials according to the weight percentage, adding hyaluronic acid, sodium alginate and tremella heteropolysaccharide into water at the water temperature of 70-80 ℃, dissolving, then adding glycerol, dihydric alcohol, trehalose and mannose, and stirring for 10-15min to obtain an aqueous solution;
(2) cooling the water solution in the step (1) to 40-45 ℃, adding lactobacillus exopolysaccharide, mussel extract, betaine, amino acid, sodium pyrrolidone carboxylate and preservative, and stirring for 15-20min to obtain the dressing.
Compared with the prior art, the invention has the beneficial effects that:
(1) according to the invention, the extracellular polysaccharide of lactic acid bacteria and the mussel extract are compounded for the first time, the tremella heteropolysaccharide, trehalose, mannose and dihydric alcohol are combined, and betaine, PCA sodium and the like are matched for scientific proportioning to prepare the dressing, so that the dressing has good anti-inflammatory and antibacterial activity and antioxidant activity, can improve the hydration capacity of skin keratinocytes, promotes the absorption of skin cuticles to nutrient components, well starts a skin wound healing mechanism, fully activates the skin repairing capacity, accelerates wound healing, promotes better and faster skin barrier repair, and better maintains skin health. The dressing prepared by the invention has good anti-inflammatory activity, high skin wound healing rate, strong skin barrier repair capacity, good tolerance and good biological safety, and can repair damaged skin better and faster.
(2) The compound lactobacillus exopolysaccharide and the mussel extract mutually promote the efficacy to be exerted, have better cell adherence effect, improve the wound healing speed, obviously improve the skin barrier repair capacity, have better biocompatibility and higher biological safety, and effectively reduce the use amount of raw materials.
(3) In addition, the invention preferably selects a certain proportion of compounded dihydric alcohol mixture, further promotes the absorption of the skin cuticle to the nutrient components, and simultaneously improves the anti-inflammatory effect of the dressing and the wound healing effect.
Detailed Description
In order to better understand the technical content of the invention, specific examples are provided below to further illustrate the invention. The experimental methods used in the examples of the present invention are all conventional methods unless otherwise specified. The materials, reagents and the like used in the examples of the present invention can be obtained commercially without specific description.
In the embodiment of the invention, the mussel extract is a commercial product and is water-soluble protein obtained by fermenting and purifying mussels.
Examples 1-3 dressing formulations
In the formula, 1, 3-propylene glycol is used as dihydric alcohol, sorbic acid is used as a preservative,
EPS: extracellular polysaccharide of lactic acid bacteria, sodium PCA: sodium pyrrolidone carboxylate.
The preparation method of the dressing of the above examples 1-3 comprises the following steps:
(1) weighing the raw materials according to the weight percentage, adding hyaluronic acid, sodium alginate and tremella heteropolysaccharide into water at the water temperature of 70-80 ℃, dissolving, then adding glycerol, dihydric alcohol, trehalose and mannose, and stirring for 10-15min to obtain an aqueous solution;
(2) cooling the water solution in the step (1) to 40-45 ℃, adding lactobacillus exopolysaccharide, mussel extract, betaine, amino acid, sodium pyrrolidone carboxylate and preservative, and stirring for 15-20min to obtain the dressing.
Example 4
This example differs from example 1 in that 1, 3-propanediol is replaced by a compounded glycol mixture of butylene glycol, methyl propylene glycol and ethyl hexanediol in a mass ratio of 0.2: 0.5: 0.3.
Comparative example 1
The difference between the comparative example and the example 1 is that the dressing comprises the following raw materials in percentage by weight: 0.08% of hyaluronic acid, 0.65% of sodium alginate, 0.20% of tremella heteropolysaccharide, 7% of glycerol, 0.8% of dihydric alcohol, 1.5% of trehalose, 1.5% of mannose, 0.08% of lactobacillus exopolysaccharide, 0.01% of mussel extract, 1.5% of betaine, 1.8% of amino acid, 1.0% of sodium pyrrolidone carboxylate, 0.02% of preservative and the balance of water.
Comparative example 2
The difference between the comparative example and the example 1 is that the dressing comprises the following raw materials in percentage by weight: 0.2% of hyaluronic acid, 1.0% of sodium alginate, 0.01% of tremella heteropolysaccharide, 5% of glycerol, 0.1% of dihydric alcohol, 2.5% of trehalose, 2.5% of mannose, 0.01% of lactobacillus exopolysaccharide, 0.09% of mussel extract, 0.5% of betaine, 1.0% of amino acid, 1.0% of sodium pyrrolidone carboxylate, 0.02% of preservative and the balance of water.
Comparative example 3
The comparative example differs from example 1 in that no exopolysaccharide of lactic acid bacteria was added and the formula was an equivalent amount of mussel extract.
Comparative example 4
The present comparative example differs from example 1 in that no mussel extract is added and the mussel extract is an equal amount of exopolysaccharide of lactic acid bacteria in the formula.
Test example 1 anti-inflammatory test
1.1 Experimental methods
143 animal KM mice with the weight of 18-21 g and the SPF level are selected and randomly divided into 11 groups, and each group comprises 13 animals, namely a blank group, a model group, a positive control group (a commercially available medical dressing of a Revimentin brand, which contains a human-like collagen stock solution) and research groups 1-8 (examples 1-4 and comparative examples 1-4). Ear skin is smeared and administrated, the positive control group and each research group are administrated for 1 time every day for 5 days continuously, after the last administration is 1h, the front and back sides of the left ear of each group of mice except the blank group are evenly smeared with 0.04mL of dimethylbenzene, and the right ear is used as a control. Killing the mice after 30min of inflammation, cutting two ears along the edge of auricle, punching the ears at the same position by using a direct 9mm puncher, weighing by using an analytical balance, taking the weight difference of the left ear and the right ear as swelling degree, calculating swelling inhibition rate, and expressing the anti-inflammatory strength of the product by using the swelling inhibition rate. The swelling inhibition rate was (difference in weight between two ears in the model group-difference in weight between two ears in the administered group)/difference in weight between two ears in the model group × 100%.
1.2 results of the experiment
Experimental results show that the dressings in the embodiments 1 to 4 of the invention can inhibit mouse ear swelling caused by xylene, and the differences have statistical significance, which shows that the dressings in the embodiments 1 to 4 of the invention have good anti-inflammatory activity, and the results are shown in Table 1.
TABLE 1 Effect on ear swelling in mice
Comparing with model group, P is less than or equal to 0.01, P is less than 0.05
Test example 2 wound healing test
1.1 Experimental methods
88 healthy rabbits with the weight of 2.3-2.8kg are selected and randomly divided into 11 groups of 8 rabbits each with half of male and female. Blank, positive control (commercially available remai medical dressing), and study groups 1-8 (examples 1-4, comparative examples 1-4), respectively. The hair on both sides of the backs of the rabbits were shaved the day before the test, with a range of about 3cm by 3 cm. The rabbits were anesthetized with pentobarbital sodium (30mg/mL), the skin of the back dehaired area was washed with iodine, the rabbit epidermis (without damaging the dermis) was lacerated with a sterile blade at 2.0cm by 1.5cm, and the epidermis was removed to form a 2.0cm by 1.5cm skin-peeled and damaged wound. Cleaning wound with normal saline, and applying to the damaged skin area at a dose of 0.5 g/kg-1·d-1. Cleaning the wound with normal saline before applying the medicine to the rabbit every dayThe administration was once at the same time point for 14 consecutive days. The healing of the rabbit wound was observed before each administration, and the mental state, activity, etc. of the rabbits after administration were observed. The wounds of the rabbits were photographed on the 14 th day of administration, respectively, and the healing of the wounds was observed: whether bleeding, penetrating fluid, suppuration, scabbing and the like exist, the size of wound healing is measured by a measuring tape, and the wound healing rate is calculated.
Wound healing rate (wound area before administration-wound area after administration)/wound area before administration 100%
1.2 results of the experiment
The result of a rabbit wound healing test shows that the dressing healing rate of the embodiment 1-4 is higher after 14 days of administration, and the difference has statistical significance compared with each research group and a positive control group. The results are shown in Table 2.
TABLE 2 wound healing of rabbits
P is less than 0.01 and less than 0.05
In conclusion, the dressings in examples 1 to 4 have good anti-inflammatory effect and high wound healing rate after 14 days of use. Compared with examples 1-3, the formula in example 1 has the best effect, is the optimal mixture ratio, and is the optimal compounding ratio of the exopolysaccharides of lactobacillus and the mussel extract. In example 4, a diol mixture compounded in a certain proportion is preferably selected, so that the absorption of the skin cuticle to the nutrient components is further promoted, and the anti-inflammatory effect and the wound healing effect of the dressing are improved. Compared with the example 1, the comparison of the comparative examples 1-2 shows that the raw material proportion is scientifically set, so that the anti-inflammatory effect of the dressing is effectively improved, the wound healing is promoted, and the skin barrier is better and faster to repair. Comparison of comparative examples 3-4 with example 1 shows that the compounded extracellular polysaccharide of lactic acid bacteria and mussel extract of the invention mutually promote the efficacy of the compound extracellular polysaccharide of lactic acid bacteria and mussel extract, improve the wound healing speed and obviously improve the skin barrier repair capacity.
Test example 3 safety test
The dressings of examples 1 to 4 were subjected to an animal skin irritation test, a skin sensitization test, and an in vitro cytotoxicity test, respectively, and the results showed safety and no toxicity.
The above results show that the above mentioned embodiments are only preferred embodiments of the present invention, and not intended to limit the present invention, and any modifications, equivalents, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (6)
1. The EPS and mussel extract compounded skin barrier repair dressing is characterized by comprising the following raw materials in percentage by weight: 0.05-0.12 percent of hyaluronic acid, 0.5-0.8 percent of sodium alginate, 0.06-0.15 percent of tremella heteropolysaccharide, 6-8 percent of glycerol, 0.3-1 percent of dihydric alcohol, 1-2 percent of trehalose, 1-2 percent of mannose, 0.02-0.05 percent of lactobacillus exopolysaccharide, 0.03-0.08 percent of mussel extract, 1-2 percent of betaine, 1.5-2.3 percent of amino acid, 1.8-2.5 percent of sodium pyrrolidone carboxylate, 0.01-0.03 percent of preservative and the balance of water.
2. The EPS and mussel extract compounded skin barrier repair dressing according to claim 1, wherein the mass ratio of the lactobacillus exopolysaccharide to the mussel extract is 4: 5.
3. The EPS and mussel extract compounded skin barrier repair dressing according to claim 1, which comprises the following raw materials in percentage by weight: 0.08% of hyaluronic acid, 0.65% of sodium alginate, 0.10% of tremella heteropolysaccharide, 7% of glycerol, 0.8% of dihydric alcohol, 1.5% of trehalose, 1.5% of mannose, 0.04% of lactobacillus exopolysaccharide, 0.05% of mussel extract, 1.5% of betaine, 1.8% of amino acid, 2.2% of sodium pyrrolidone carboxylate, 0.02% of preservative and the balance of water.
4. The EPS and mussel extract compounded skin barrier repair dressing according to claim 1, wherein the glycol is at least one of 1, 3-propanediol, dipropylene glycol, butylene glycol, methyl propanediol, and ethyl hexanediol.
5. The EPS and mussel extract compounded repairing skin barrier dressing according to claim 4, wherein the glycol is selected from butylene glycol, methyl propylene glycol and ethyl hexanediol at a mass ratio of 0.2: 0.5: 0.3.
6. The method for preparing the EPS and mussel extract compounded skin barrier repair dressing according to any one of claims 1 to 5, which comprises the following steps:
(1) weighing the raw materials according to the weight percentage, adding hyaluronic acid, sodium alginate and tremella heteropolysaccharide into water at the water temperature of 70-80 ℃, dissolving, then adding glycerol, dihydric alcohol, trehalose and mannose, and stirring for 10-15min to obtain an aqueous solution;
(2) cooling the water solution in the step (1) to 40-45 ℃, adding lactobacillus exopolysaccharide, mussel extract, betaine, amino acid, sodium pyrrolidone carboxylate and preservative, and stirring for 15-20min to obtain the dressing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110604155.6A CN113368300B (en) | 2021-05-31 | 2021-05-31 | EPS and mussel extract compounded dressing for repairing skin barrier and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110604155.6A CN113368300B (en) | 2021-05-31 | 2021-05-31 | EPS and mussel extract compounded dressing for repairing skin barrier and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113368300A true CN113368300A (en) | 2021-09-10 |
| CN113368300B CN113368300B (en) | 2022-05-17 |
Family
ID=77574968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110604155.6A Active CN113368300B (en) | 2021-05-31 | 2021-05-31 | EPS and mussel extract compounded dressing for repairing skin barrier and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113368300B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114569515A (en) * | 2022-03-28 | 2022-06-03 | 绽妍生物科技有限公司 | Hydrogel for repairing damaged skin barrier after medical and art and preparation method thereof |
| CN114668889A (en) * | 2022-03-30 | 2022-06-28 | 绽妍生物科技有限公司 | Regeneration and repair dressing containing mussel-like mucin and preparation method thereof |
| CN114767924A (en) * | 2022-04-29 | 2022-07-22 | 海南德诺海思生物科技有限公司 | Preparation method of mussel-like mucin hydrogel suitable for repairing damaged skin cells |
| CN114869836A (en) * | 2022-05-23 | 2022-08-09 | 绽妍生物科技有限公司 | EPS composite acid skin-refreshing gel and preparation method and application thereof |
| CN115624647A (en) * | 2022-11-10 | 2023-01-20 | 北京科技大学 | Biological film medical dressing compounded with wound healing medicine and film essence, and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017101021A1 (en) * | 2015-12-15 | 2017-06-22 | 江阴市本特塞缪森生命科学研究院有限公司 | Modified bone repairing material |
| CN110448521A (en) * | 2019-08-30 | 2019-11-15 | 英科博雅集团有限公司 | Stem Cell Activity factor facial mask sticking dressing and preparation method for skin repair |
| CN111621532A (en) * | 2020-07-15 | 2020-09-04 | 辽宁大学 | Preparation method of lactobacillus extracellular polysaccharide and derivatives thereof |
| CN112370364A (en) * | 2020-11-24 | 2021-02-19 | 西安润玉医疗科技有限公司 | Bionic composition for repairing skin barrier and preparation method thereof |
| CN112656709A (en) * | 2021-01-06 | 2021-04-16 | 华熙生物科技股份有限公司 | Skin care compositions and uses thereof |
-
2021
- 2021-05-31 CN CN202110604155.6A patent/CN113368300B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017101021A1 (en) * | 2015-12-15 | 2017-06-22 | 江阴市本特塞缪森生命科学研究院有限公司 | Modified bone repairing material |
| CN110448521A (en) * | 2019-08-30 | 2019-11-15 | 英科博雅集团有限公司 | Stem Cell Activity factor facial mask sticking dressing and preparation method for skin repair |
| CN111621532A (en) * | 2020-07-15 | 2020-09-04 | 辽宁大学 | Preparation method of lactobacillus extracellular polysaccharide and derivatives thereof |
| CN112370364A (en) * | 2020-11-24 | 2021-02-19 | 西安润玉医疗科技有限公司 | Bionic composition for repairing skin barrier and preparation method thereof |
| CN112656709A (en) * | 2021-01-06 | 2021-04-16 | 华熙生物科技股份有限公司 | Skin care compositions and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| 付思娅等: "《面膜研究进展探析》", 《化工管理》 * |
| 刘文: "《药用高分子材料学》", 30 June 2017, 中国中医药出版社 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114569515A (en) * | 2022-03-28 | 2022-06-03 | 绽妍生物科技有限公司 | Hydrogel for repairing damaged skin barrier after medical and art and preparation method thereof |
| CN114569515B (en) * | 2022-03-28 | 2023-07-07 | 绽妍生物科技有限公司 | Hydrogel for repairing damaged skin barrier after medical arts and preparation method thereof |
| CN114668889A (en) * | 2022-03-30 | 2022-06-28 | 绽妍生物科技有限公司 | Regeneration and repair dressing containing mussel-like mucin and preparation method thereof |
| CN114767924A (en) * | 2022-04-29 | 2022-07-22 | 海南德诺海思生物科技有限公司 | Preparation method of mussel-like mucin hydrogel suitable for repairing damaged skin cells |
| CN114869836A (en) * | 2022-05-23 | 2022-08-09 | 绽妍生物科技有限公司 | EPS composite acid skin-refreshing gel and preparation method and application thereof |
| CN114869836B (en) * | 2022-05-23 | 2024-01-12 | 绽妍生物科技有限公司 | EPS composite acid skin-refreshing gel and preparation method and application thereof |
| CN115624647A (en) * | 2022-11-10 | 2023-01-20 | 北京科技大学 | Biological film medical dressing compounded with wound healing medicine and film essence, and preparation method and application thereof |
| CN115624647B (en) * | 2022-11-10 | 2023-12-12 | 北京科技大学 | Biological film medical dressing compounded with wound healing medicine and film essence, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113368300B (en) | 2022-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113368300B (en) | EPS and mussel extract compounded dressing for repairing skin barrier and preparation method thereof | |
| EP2452673B1 (en) | Chitosan gel for dermatological use, production method therefor and use of same | |
| KR102212023B1 (en) | Water-soluble hyaluronic acid gel and method for producing same | |
| CN113117137A (en) | Medical dressing containing recombinant human collagen and preparation method thereof | |
| EP2979685B1 (en) | Film forming complex, cosmetic composition comprising it and their use as peel-off film mask | |
| CN111529478A (en) | Moisturizing hand-washing-free disinfectant and preparation method thereof | |
| CN108524406A (en) | A kind of Golden flower facial mask and preparation method thereof | |
| CN110638727A (en) | Infant hip-protecting composition and preparation method and application thereof | |
| CN106389139A (en) | Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof | |
| CN109010124B (en) | Marine refined gynecological antibacterial gel and preparation method thereof | |
| CN107375152A (en) | A kind of cation sterilization gel and preparation method thereof and the aloetic bacteriostatic gel product comprising the cation sterilization gel | |
| CN110917120A (en) | Sticky antibacterial repairing material and preparation method and application thereof | |
| CN112107724A (en) | Liquid dressing and preparation method thereof | |
| CN113925814A (en) | Moisturizing essence containing yeast green tea fermentation product and preparation method thereof | |
| CN109157673A (en) | A kind of liquid adhesive bandage | |
| CN111514161B (en) | Anti-oral ulcer preparation and application thereof | |
| CN113662904A (en) | Acne-removing patch aerosol and preparation method thereof | |
| KR101835799B1 (en) | A cosmetic composition for manufacturing by the using of propolis, and the cosmetic manufactured by the composition | |
| WO2018138221A1 (en) | Hyaluronic acid cross-linked with natural or semi-synthetic crosslinking agents | |
| CN112022795A (en) | Skin care and repair composition, preparation method and application thereof | |
| CN111557862A (en) | Medical recombinant human collagen and preparation method thereof | |
| CN107149569A (en) | A kind of antipruritic skin gels composition | |
| CN110193017B (en) | Film spraying agent for promoting hair growth and preparation method thereof | |
| CN111870590B (en) | Liquid acne-removing patch and preparation method thereof | |
| CN113230200A (en) | Ointment for treating bacterial skin diseases and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: No. 3701, 37th Floor, Building 2, No. 666, Middle Tianfu Avenue, Chengdu High-tech Zone, China (Sichuan) Pilot Free Trade Zone, Chengdu, Sichuan 610000 Patentee after: Chunyan Biotechnology Co.,Ltd. Address before: 37th floor, building 2, No. 666, middle section of Tianfu Avenue, Chengdu hi tech Zone, China (Sichuan) pilot Free Trade Zone, Chengdu, Sichuan 610000 Patentee before: Chayan Biotechnology Co.,Ltd. |